Abiopharma

🔍 Charlton Kevin M. (Director)

Company: Evolv Technologies Holdings, Inc. (EVLV)

Report Date: 2026-06-17

Detailed Transactions and Holdings:

• Acquired 27,050 shares of Class A Common Stock (Direct)
  Date: 2026-06-17 | Code: M | equity_swap_involved: 0 | shares_owned_after: 359,010.00 | transaction_form_type: 4
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-06-17 | Code: H | nature_of_ownership: By IRA | shares_owned_after: 44,081.00
• Sold 27,050 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-17 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F2, F1
• Acquired 28,318 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-18 | Code: A | equity_swap_involved: 0 | shares_owned_after: 28,318.00 | transaction_form_type: 4 | Footnotes: F1, F3, F1

Footnotes:

• F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A common stock. The RSUs have no expiration date.
• F2: The RSUs vested in full on June 17, 2026.
• F3: The RSUs will vest in full at the earlier of June 18, 2027 or the day immediately preceding the Issuer's next annual meeting date.